Skip to content

BillionToOne

US · BLLN #2109 by market cap Listed 2025
89.92 -0.28 -0.31%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Valuation each multiple against its own 5-year range

P/B ratio 8.87 Expensive vs history 70th percentile
5-year average 0.70 · #34 of 41 in Diagnostics & Research
P/E ratio 108.96 In line with history 46th percentile
5-year average 171.49 · forward 102.42 · #18 of 20 in Diagnostics & Research
P/S ratio 11.50 Cheap vs history 26th percentile
5-year average 13.59 · forward 9.29 · #34 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
BillionToOne (BLLN) 4.30B 93.18 7.58 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value104.72 Economic moatNone UncertaintyHigh

Trading 16.5% below Morningstar's fair value estimate.

Fair value

BillionToOne Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a price consistent with our quantitative fair value estimate, which has a high uncertainty rating.

The firm's lack of profitability weakens our fair value estimate. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. Reflecting the firm's profitability is its sales yield of 18.1%, which sits in the bottom 20% globally. This company's inability to generate significant sales growth without meaningful capital investment is a challenge, which contributes to our balanced fair value estimate.

The firm's valuation metrics are an additional cause for concern. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's book value yield of 10.4%, for example, lies in the bottom 10% compared with global peers. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which further promotes our neutral price/fair value ratio.

Economic moat

This company lacks a competitive advantage, receiving a quantitative economic moat rating of none. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-11-20 20:01:12 · For reference only, not investment advice and not tailored to your situation.

BillionToOne discussion 0 comments

Add a comment